Management of Non-selected Children with Childhood Chronic Immune Thrombocytopenic Purpura

Posted on

A new study described the management of non-selected children with childhood chronic immune thrombocytopenic purpura (cITP) in France. Since 2004, this national prospective cohort enrolled patients under >18 years old who were diagnosed with cITP. During the median follow-up of 6 years, 45% of patients did not need second-line therapy, and 55% (n = 217) received one or more second lines, mainly splenectomy (n = 108), hydroxychloroquine (n = 61), rituximab (n = 61) or azathioprine (n = 40). Overall 5-year further second-line treatment-free survival was 56% [95% CI 49·5-64.1]. Complete remission was achieved in 55% of the 56 children followed.

The authors concluded that “children with cITP do not need second-line treatments in 45% of cases.”

Read the full study here.

Ducassou S, Gourdonneau A, Fernandes H, et al. Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the french experience over the past 25 years. Br J Haematol. 2020;[Online ahead of print]. DOI: 10.1111/bjh.16448.

Related Articles
Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment
Jun 01, 2021
ASH: Novel Fetal Hemoglobin Repressor for Sickle Cell Disease Identified
May 31, 2020
Education and Support Enhance Care for Rare-Disease Patients
Mar 27, 2020